医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific Symposium

2020年02月05日 PM10:01
このエントリーをはてなブックマークに追加


 

WALTHAM, Mass.

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axial’s Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders Inaugural Scientific Symposium on Thursday, February 6, 2020 at 11:00 AM AEST (Wednesday, February 5, 2020, 7:00 PM ET) at the Queensland Children’s Hospital in South Brisbane, Queensland, Australia.

About Axial Biotherapeutics

Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005198/en/

CONTACT

Investor Contact:

Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

julie.seidel@sternir.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生